Bristol-Myers Squibb Weighs Options On Mead Johnson
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb could reap as much as $10 billion by selling its Mead Johnson nutritional business and other non-pharmaceutical units, analysts say